Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep 1;85(9):1247–1250. doi: 10.1054/bjoc.2001.2071

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)

G-S Wang 1, K-Y Yang 1, R-P Perng 1
PMCID: PMC2375237  PMID: 11720456

Abstract

4 patients with advanced non-small-cell lung cancer (NSCLC) treated with docetaxel developed life-threatening pneumonitis requiring mechanical ventilation. Docetaxel (30–60 mg m−2, according to a different protocol) was infused within one hour with standard premedications. One patient's pneumonitis occurred 5 days after the first dose of docetaxel, and that of the other 3 between the 2nd and 6th cycles. Based on the clinical course, radiological findings of an interstitial pneumonitis, and exclusion of other possible resultant causes, including metastatic cancer, radiation pulmonary injury, infection, or connective tissue disease, hypersensitivity pneumonitis was diagnosed. The patients were treated with hydrocortisone at 1200 mg per day or methylprednisolone at 240 mg per day. Although 3 of the 4 had a partial improvement in lung oxygenation, all patients’ conditions of hypersensitivity pneumonitis persisted and were complicated by other events, such as hospital-acquired infection and tension pneumothorax. The presence of this unusual hypersensitivity pneumonitis, which was so severe as to be life-threatening and refractory to high-dose corticosteroid therapy, should be taken into account during docetaxel treatment. © 2001 Cancer Research Campaign

Keywords: docetaxel, non-small-cell lung cancer, hypersensitivity pneumonitis

Full Text

The Full Text of this article is available as a PDF (64.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akoun G. M., Liote H. A., Liote F., Gauthier-Rahman S., Kuntz D. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis. Chest. 1990 Feb;97(2):495–498. doi: 10.1378/chest.97.2.495. [DOI] [PubMed] [Google Scholar]
  2. Akoun G. M., Milleron B. J., Mayaud C. M., Tholoniat D. Provocation test coupled with bronchoalveolar lavage in diagnosis of propranolol-induced hypersensitivity pneumonitis. Am Rev Respir Dis. 1989 Jan;139(1):247–249. doi: 10.1164/ajrccm/139.1.247. [DOI] [PubMed] [Google Scholar]
  3. Choy H., Safran H., Akerley W., Graziano S. L., Bogart J. A., Cole B. F. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 1998 Aug;4(8):1931–1936. [PubMed] [Google Scholar]
  4. Cooper J. A., Jr, White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986 Feb;133(2):321–340. doi: 10.1164/arrd.1986.133.2.321. [DOI] [PubMed] [Google Scholar]
  5. Cooper J. A., Jr, White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. Am Rev Respir Dis. 1986 Mar;133(3):488–505. doi: 10.1164/arrd.1986.133.3.488. [DOI] [PubMed] [Google Scholar]
  6. Earhart R. H. Docetaxel (Taxotere): preclinical and general clinical information. Semin Oncol. 1999 Oct;26(5 Suppl 17):8–13. [PubMed] [Google Scholar]
  7. Etienne B., Pérol M., Nesme P., Vuillermoz S., Robinet G., Guérin J. C. Pneumopathie interstitielle diffuse aiguë sous docétaxel (Taxotère). A propos de 2 observations. Rev Mal Respir. 1998 Apr;15(2):199–203. [PubMed] [Google Scholar]
  8. Fossella F. V. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol. 1999 Oct;26(5 Suppl 16):17–42. [PubMed] [Google Scholar]
  9. Fujimori K., Yokoyama A., Kurita Y., Uno K., Saijo N. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology. 1998 Jul-Aug;55(4):340–344. doi: 10.1159/000011873. [DOI] [PubMed] [Google Scholar]
  10. Furuse K., Naka N., Takada M., Kinuwaki E., Kudo S., Takada Y., Yamakido M., Yamamoto H., Fukuoka M. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology. 1997 Jul-Aug;54(4):298–303. doi: 10.1159/000227707. [DOI] [PubMed] [Google Scholar]
  11. Guillon J. M., Joly P., Autran B., Denis M., Akoun G., Debré P., Mayaud C. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med. 1992 Sep 15;117(6):476–481. doi: 10.7326/0003-4819-117-6-476. [DOI] [PubMed] [Google Scholar]
  12. Holoye P. Y., Luna M. A., MacKay B., Bedrossian C. W. Bleomycin hypersensitivity pneumonitis. Ann Intern Med. 1978 Jan;88(1):47–49. doi: 10.7326/0003-4819-88-1-47. [DOI] [PubMed] [Google Scholar]
  13. Ibrahim N. K., Sahin A. A., Dubrow R. A., Lynch P. M., Boehnke-Michaud L., Valero V., Buzdar A. U., Hortobagyi G. N. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22;355(9200):281–283. doi: 10.1016/S0140-6736(99)06195-4. [DOI] [PubMed] [Google Scholar]
  14. Jantz M. A., Sahn S. A. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med. 1999 Oct;160(4):1079–1100. doi: 10.1164/ajrccm.160.4.9901075. [DOI] [PubMed] [Google Scholar]
  15. Keller R. H., Swartz S., Schlueter D. P., Bar-Sela S., Fink J. N. Immunoregulation in hypersensitivity pneumonitis: phenotypic and functional studies of bronchoalveolar lavage lymphocytes. Am Rev Respir Dis. 1984 Nov;130(5):766–771. doi: 10.1164/arrd.1984.130.5.766. [DOI] [PubMed] [Google Scholar]
  16. Khan A., McNally D., Tutschka P. J., Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother. 1997 Dec;31(12):1471–1474. doi: 10.1177/106002809703101205. [DOI] [PubMed] [Google Scholar]
  17. Kunitoh H., Watanabe K., Onoshi T., Furuse K., Niitani H., Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996 May;14(5):1649–1655. doi: 10.1200/JCO.1996.14.5.1649. [DOI] [PubMed] [Google Scholar]
  18. Merad M., Le Cesne A., Baldeyrou P., Mesurolle B., Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann Oncol. 1997 Feb;8(2):191–194. doi: 10.1023/a:1008226416896. [DOI] [PubMed] [Google Scholar]
  19. Münster P. N., Hudis C. A. Role of taxanes in adjuvant therapy. Cancer Invest. 2000;18(1):32–38. doi: 10.3109/07357900009023060. [DOI] [PubMed] [Google Scholar]
  20. Schweitzer V. G., Juillard G. J., Bajada C. L., Parker R. G. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995 Sep 15;76(6):1069–1072. doi: 10.1002/1097-0142(19950915)76:6<1069::aid-cncr2820760623>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  21. Tamura T., Sasaki Y., Nishiwaki Y., Saijo N. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res. 1995 Dec;86(12):1203–1209. doi: 10.1111/j.1349-7006.1995.tb03316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vaishampayan U., Parchment R. E., Jasti B. R., Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology. 1999 Dec;54(6A):22–29. doi: 10.1016/s0090-4295(99)00451-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES